[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544040":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":79,"collaborators":22,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":22,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":22,"enrollmentInfo":90,"targetDuration":22,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":102,"whyStopped":22,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab+Carboplatin+Paclitaxel","EXPERIMENTAL","Tislelizumab 200mg D1 +Carboplatin(AUC=5) D1+Paclitaxel(175 mg\u002Fm2 ) D1, every 3 weeks (21 days) is a treatment cycle",[13,14,15],"Drug: Tislelizumab","Drug: Paclitaxel","Drug: Carboplatin",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tislelizumab","Tislelizumab 200mg D1 ,Q3W",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Paclitaxel","Paclitaxel(175 mg\u002Fm2 ) D1,Q3W",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Carboplatin","Carboplatin(AUC=5) D1,Q3W",[9],[32],{"name":33,"affiliation":34,"role":35},"Zheng Hu, MD,PhD","Wuhan University","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},"CONTACT","13632120686","Huzheng1988@163.com",[42,60,68],{"facility":43,"status":22,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Central Hospital of Wuhan","Wuhan","Hubei","430014","China","CN",{"type":50,"coordinates":51},"Point",[52,53],114.26667,30.58333,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":58,"phoneExt":22,"email":59},"Xun Tian, MD,PhD","15327205656","tianxun@126.com",{"facility":61,"status":22,"city":44,"state":45,"zip":62,"country":47,"countryCode":48,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Zhongnan Hospital of Wuhan University","430062",{"type":50,"coordinates":64},[52,53],{"lat":53,"lon":52},[67],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},{"facility":69,"status":22,"city":44,"state":45,"zip":70,"country":47,"countryCode":48,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Hubei maternal and child health care hospital","430070",{"type":50,"coordinates":72},[52,53],{"lat":53,"lon":52},[75],{"name":76,"role":38,"phone":77,"phoneExt":22,"email":78},"QuanFu Ma, MD,PhD","13728133014","dm626925@126.com",{"type":80,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100544040","tislelizumab-in-combination-with-chemotherapy-as-a-neoadjuvant-treatment-for-advanced-endometrial-cancer-100544040",false,"NCT06363708","Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer","Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study","Inclusion Criteria:\n\n1. Voluntary participation and signed informed consent form;\n2. Age ≥18 years;\n3. Eastern Cooperative Oncology Group performance status 0-1;\n4. The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer;\n5. Has not received any systematic anti-tumor treatment for advanced diseases in the past;\n6. Have measurable disease according to RECIST v1.1 criteria;\n7. Patients must meet the following criteria for laboratory tests to ensure adequate organ function:\n\n   * ANC ≥1,500\u002Fmm3, or ≥1.5×109\u002FL\n   * Platelet count≥75,000\u002Fmm3 or 75 x 109\u002FL\n   * Hemoglobin≥9 g\u002FdL or ≥5.6 mmol\u002FL\n   * Glomerular filtration rate estimated（eGFR） according to the Chronic Kidney Disease Epidemiology Collaborative Group formula （CKD-EPI EQ6）was≥40 mL\u002F 1.73m2\n   * Serum total bilirubin ≤ 1.5x upper limit of normal range（ULN）\n   * Both AST and ALT were ≤3 x ULN\n8. The expected lifespan exceeds 3 months.\n\nExclusion Criteria:\n\n1. Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment；\n2. Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection；\n3. Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure;\n4. Major surgical procedures had been performed within 4 weeks before consent was obtained；\n5. Other conditions deemed by the investigator to be ineligible for enrollment.","FEMALE","18 Years",{"count":91,"type":92},20,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.",[98],"Endometrial Neoplasms",[100,101,19],"Oncology","Endometrial Cancer","NOT_YET_RECRUITING","2024-04-11",{"date":105,"type":106},"2024-04-12","ACTUAL",{"date":108,"type":92},"2024-06-01",{"date":110,"type":92},"2026-06-30",{"name":5,"class":6},3]